Vicarious Surgical Inc has a consensus price target of $6 based on the ratings of 14 analysis. The 3 most-recent analyst ratings were released by Piper Sandler, Morgan Stanley, and Canaccord Genuity on March 5, 2024, December 4, 2023, and November 14, 2023, respectively. With an average price target of $0.67 between Piper Sandler, Morgan Stanley, and Canaccord Genuity, there's an implied -92.71% downside for Vicarious Surgical Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/05/2024 | Buy Now | -89.07% | Piper Sandler | Adam Maeder | $45 → $30 | Maintains | Neutral | Get Alert |
12/04/2023 | Buy Now | -93.44% | Morgan Stanley | Patrick Wood | → $18 | Initiates | → Equal-Weight | Get Alert |
11/14/2023 | Buy Now | — | BTIG | Ryan Zimmerman | — | Downgrade | Buy → Neutral | Get Alert |
11/14/2023 | Buy Now | -95.63% | Canaccord Genuity | Caitlin Cronin | $270 → $12 | Downgrade | Buy → Hold | Get Alert |
05/31/2023 | Buy Now | -1.64% | Canaccord Genuity | Kyle Rose | $360 → $270 | Maintains | Buy | Get Alert |
07/18/2022 | Buy Now | -23.5% | BTIG | Ryan Zimmerman | $240 → $210 | Maintains | Buy | Get Alert |
05/10/2022 | Buy Now | -45.36% | Piper Sandler | Adam Maeder | $210 → $150 | Maintains | Neutral | Get Alert |
03/04/2022 | Buy Now | 42.08% | Canaccord Genuity | Kyle Rose | $450 → $390 | Maintains | Buy | Get Alert |
03/04/2022 | Buy Now | -23.5% | Piper Sandler | Adam Maeder | $480 → $210 | Downgrade | Overweight → Neutral | Get Alert |
01/07/2022 | Buy Now | 74.86% | Credit Suisse | Matt Miksic | → $480 | Initiates | → Outperform | Get Alert |
12/07/2021 | Buy Now | 63.93% | Cowen & Co. | Joshua Jennings | → $450 | Initiates | → Outperform | Get Alert |
11/05/2021 | Buy Now | 63.93% | Canaccord Genuity | Kyle Rose | → $450 | Initiates | → Buy | Get Alert |
10/18/2021 | Buy Now | 63.93% | BTIG | Ryan Zimmerman | → $450 | Initiates | → Buy | Get Alert |
10/07/2021 | Buy Now | 74.86% | Piper Sandler | Adam Maeder | → $480 | Initiates | → Overweight | Get Alert |
The latest price target for Vicarious Surgical (NYSE:RBOT) was reported by Piper Sandler on March 5, 2024. The analyst firm set a price target for $1.00 expecting RBOT to fall to within 12 months (a possible -89.07% downside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Vicarious Surgical (NYSE:RBOT) was provided by Piper Sandler, and Vicarious Surgical maintained their neutral rating.
There is no last upgrade for Vicarious Surgical
The last downgrade for Vicarious Surgical Inc happened on November 14, 2023 when BTIG changed their price target from N/A to N/A for Vicarious Surgical Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vicarious Surgical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vicarious Surgical was filed on March 5, 2024 so you should expect the next rating to be made available sometime around March 5, 2025.
While ratings are subjective and will change, the latest Vicarious Surgical (RBOT) rating was a maintained with a price target of $1.50 to $1.00. The current price Vicarious Surgical (RBOT) is trading at is $9.15, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.